Trial Profile
An Open-Label Phase 1 Study to Determine the Absorption, Metabolism, and Routes of Excretion Following Oral Administration of (14C) Radiolabeled JNJ-42756493 to Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Oct 2019
Price :
$35
*
At a glance
- Drugs Erdafitinib (Primary)
- Indications Breast cancer; Cancer; Cholangiocarcinoma; Gastric cancer; Liver cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Solid tumours; Urogenital cancer
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Oct 2019 Results of a cross-study analysis of total 7 studies(NCT01703481,NCT02218073,NCT02231489,EuDRACT-2015-001583-19,NCT02692677,NCT03066687and NCT03135106) published in the Journal of Clinical Pharmacology
- 30 Sep 2016 Status changed from recruiting to completed.
- 12 May 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.